Legal & General Group
NYMX

Legal & General Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Legal & General Group’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,778
Closed -$11K – 3702
2021
Q1 		$11K Hold
4,778
– – ﹤0.01% 3361
2020
Q4 		$12K Hold
4,778
– – ﹤0.01% 3287
2020
Q3 		$12K Sell
4,778
-1,539
-24% -$4.48K ﹤0.01% 3179
2020
Q2 		$22K Buy
+6,317
New +$20K ﹤0.01% 3038
2019
Q3 		– Sell
-4,420
Closed -$7K – 3440
2019
Q2 		$7K Hold
4,420
– – ﹤0.01% 3422
2019
Q1 		$9K Hold
4,420
– – ﹤0.01% 3267
2018
Q4 		$6K Hold
4,420
– – ﹤0.01% 3327
2018
Q3 		$11K Hold
4,420
– – ﹤0.01% 3318
2018
Q2 		$15K Sell
4,420
-2,421
-35% -$9.3K ﹤0.01% 3256
2018
Q1 		$29K Hold
6,841
– – ﹤0.01% 2999
2017
Q4 		$22K Buy
6,841
+2,647
+63% +$9.65K ﹤0.01% 3134
2017
Q3 		$16K Hold
4,194
– – ﹤0.01% 3221
2017
Q2 		$18K Buy
+4,194
New +$17.2K ﹤0.01% 3228

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TEE
Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Legal & General Group's NYMX Position: Q2 2021 in Review

Legal & General Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2021, closing a stake of 4,778 shares — an estimated $11K sold.

Legal & General Group first reported a position in NYMX in Q2 2017 and held it in 13 quarters. The position peaked at $29K in Q1 2018. 51 funds tracked by Wall St. Rank hold NYMX as of Q2 2021.

  • Legal & General Group reported no remaining Nymox Pharmaceutical Corp position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 4,778 Nymox Pharmaceutical Corp shares in Q2 2021, an estimated $11K.
  • Legal & General Group first reported a position in Nymox Pharmaceutical Corp in Q2 2017 and held it in 13 quarters.
  • Legal & General Group's Nymox Pharmaceutical Corp position peaked at $29K in Q1 2018.
  • 51 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.